Why UTIs keep coming back
Most UTIs are caused by E. coli from the gut finding its way into the urethra and bladder. Women are anatomically more vulnerable โ shorter urethra, proximity of the urethra to the rectum. But recurrent UTIs aren't just bad luck. They usually reflect a pattern: a disrupted vaginal microbiome, low estrogen (particularly in perimenopause and menopause), or a specific behavioral trigger like post-sex urination habits or contraceptive choice.
For a lot of women, the first UTI response is antibiotics, which work but also wipe out the Lactobacillus-dominant vaginal environment that was protecting the bladder. The next UTI comes sooner. The pattern accelerates. The solution isn't to keep taking antibiotics for the same infection โ it's to figure out what's letting bacteria establish a foothold in the first place.
The D-mannose problem
D-mannose became the supplement-of-choice for UTI prevention largely because of a plausible mechanism: the sugar was supposed to bind to E. coli and prevent bacteria from sticking to bladder walls, flushing them out in urine. The mechanism made sense. The problem is that the clinical trials didn't follow.
In 2024, JAMA Internal Medicine published a randomized controlled trial of daily D-mannose in women with recurrent UTIs in primary care. The result: D-mannose did not reduce the proportion of women who experienced a subsequent UTI compared to placebo. A 2025 meta-analysis of multiple RCTs reached the same conclusion. The American Urological Association's 2025 updated guidance explicitly noted that D-mannose should not be routinely recommended for UTI prevention based on current evidence.
The 2024 JAMA Internal Medicine trial enrolled women aged 18โ65 with at least two confirmed UTIs in the previous year. Participants received either daily D-mannose (2g) or placebo for six months. Primary outcome: a clinically suspected UTI requiring antibiotic treatment. Result: no statistically significant difference between groups. The trial was adequately powered, double-blind, and well-designed โ not a small or poorly controlled study. This is the kind of evidence that warrants updating the D-mannose recommendation.
What does have evidence behind it
Vaginal estrogen (for women in perimenopause or postmenopause)
Low estrogen changes the vaginal environment significantly โ the Lactobacillus-dominant microbiome shifts, pH rises, and the tissue thins. Topical vaginal estrogen cream or a ring restores that environment. Multiple studies and meta-analyses show that it meaningfully reduces recurrent UTI rates in postmenopausal women. This is the highest-quality evidence available for any non-antibiotic UTI prevention approach.
It's worth noting explicitly: vaginal estrogen is low-dose, absorbed locally rather than systemically, and is considered safe for most women including many with breast cancer history. Yet it is dramatically underutilized. If you're perimenopausal or postmenopausal and having recurrent UTIs, asking specifically about vaginal estrogen is the most impactful conversation you can have.
Lactobacillus crispatus intravaginal suppositories
A well-designed RCT found that women using a Lactobacillus crispatus suppository had a recurrence rate of 15% versus 27% in the placebo group. That's a meaningful reduction, and it directly addresses the vaginal microbiome disruption that underlies many recurrent UTI patterns.
This specific probiotic strain and delivery method (intravaginal suppository, not oral capsule) is important โ most oral probiotic products marketed for UTI prevention do not contain Lactobacillus crispatus at the needed dose or form. This area is actively developing and not all products are equal.
Low-dose prophylactic antibiotics (for high-frequency recurrence)
For women with truly frequent recurrences (3 or more per year), post-coital antibiotic prophylaxis or low-dose continuous antibiotic prophylaxis is evidence-based and appropriate. This is a clinical conversation, not a supplement decision. The hesitation to prescribe it is sometimes higher than warranted. If you've had recurrent UTIs for years without a prevention plan, this is worth raising directly.
Urinating promptly after sex reduces UTI risk โ this one is genuinely supported. Staying well hydrated helps by increasing urinary flow and flushing bacteria. Wiping front to back reduces fecal contamination. Avoiding spermicides (which disrupt the vaginal microbiome) if you're prone to recurrence is worth trying. Cranberry extract has weak evidence at best โ not harmful, but not the reliable prevention tool it's often marketed as.
What to tell your doctor
- Keep a log: number of UTIs per year, when they tend to cluster (post-sex, certain times of cycle, after antibiotic courses), and what antibiotic was used. This pattern helps your doctor select the right prevention approach.
- If you're in perimenopause or postmenopause, ask specifically about low-dose vaginal estrogen for UTI prevention โ not just as a symptom treatment. It's the most evidence-backed non-antibiotic option available.
- Ask whether antibiotic prophylaxis is appropriate for your frequency โ either post-coital or continuous low-dose. This is a well-established clinical option that is sometimes not offered until patients ask.
- If recurrent UTIs are diagnosed only by symptoms without urine cultures, ask for a culture. Symptoms can sometimes overlap with overactive bladder or interstitial cystitis, which require entirely different management.
When a recurrent UTI needs further investigation
If you've had three or more confirmed UTIs in 12 months, or if UTIs keep coming back within weeks of completing antibiotics, a urology referral is appropriate. Recurrent UTI in younger women can sometimes indicate anatomical factors; in older women it may reflect pelvic floor changes or incomplete bladder emptying. Imaging and cystoscopy are not always necessary but are worth discussing if the pattern is persistent and prevention has failed.
References
- Harding C, et al. d-Mannose for Prevention of Recurrent Urinary Tract Infection Among Women: A Randomized Clinical Trial. JAMA Internal Medicine. 2024;184(6). doi:10.1001/jamainternmed.2024.0264
- D-mannose for prevention of recurrent urinary tract infection in adult women: An updated systematic review and meta-analysis. PMC. 2025. pmc.ncbi.nlm.nih.gov
- Prevention of Recurrent Urinary Tract Infection in Women: An Update. Pharmacy. 2024;12(3). doi:10.3390/pharmacy12030066
- Ackerman AL. New Perspectives in the Management of Recurrent Urinary Tract Infections. AUA News. September 2025. auanews.net